Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,935 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT00880061 | An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma | terminated | Phase 1 | 7 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 |
| Jul 5, 2018 |
| clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01644955 | Carboplatin in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 10 | James ElderOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02345824 | Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma | unknown | Phase 1 | 3 | University of VirginiaOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | completed | Phase 1 | 54 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | completed | Phase 1 | 58 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | completed | Phase 1 | 17 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT02305056 | Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)(CARBONOMIC) | terminated | Phase 1 | 6 | University Hospital, GrenobleOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00990496 | A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | terminated | Phase 1 | 25 | Milton S. Hershey Medical CenterOTHER | 0 | May 2, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | terminated | Phase 1 | 1 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02840123 | Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines | unknown | Phase 1 | 10 | Fundació Sant Joan de DéuOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma | terminated | Phase 1 | 30 | ActelionINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT00766753 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 22 | Frank LiebermanOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00693095 | Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer(ERaDICATe) | completed | Phase 1 | 23 | John SampsonOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | terminated | Phase 1 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01171469 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | completed | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01800695 | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | completed | Phase 1 | 202 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | terminated | Phase 1 | 26 | Patrick Y. Wen, MDOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02122822 | Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 | completed | Phase 1 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02510950 | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma(D24GBM) | completed | Phase 1 | 31 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01975116 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | completed | Phase 1 | 18 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 7, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01526837 | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence | terminated | Phase 1 | 1 | Brain & Spine Surgeons of New YorkOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01182883 | A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00694330 | Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor | completed | Phase 1 | 11 | Massachusetts General HospitalOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT02648633 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | terminated | Phase 1 | 4 | University of VirginiaOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01393912 | PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma | completed | Phase 1 | 55 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01792505 | Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma | completed | Phase 1 | 71 | Cedars-Sinai Medical CenterOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00792012 | A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 37 | University of Colorado, DenverOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00185848 | Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis | completed | Phase 1 | 10 | Sanjiv Sam GambhirOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00859222 | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 51 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01902771 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | terminated | Phase 1 | 1 | Edward ZigaOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Deaconess Medical CenterOTHER | 1 | Mar 6, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 19, 2018source: clinicaltrials